The wearable pump is designed to provide a continuous subcutaneous infusion of Supernus’ apomorphine (Apokyn). The drug is ...

In connection with the financing, Serina issued 965,250 shares of convertible preferred stock at $5.18 per share, equivalent to the closing price of its common stock on April 7, 2025.

AbbVie asked for Produodopa to be considered for use in patients who cannot have apomorphine – an ... from other subcutaneous infusion therapies, notably Mitsubishi Tanabe Pharma’s ND-0612 ...